Everything to Know about Jeuveau, Plus More of Your Questions Answered

You've heard us discuss neuromodulators on the podcast before, but they aren't one-size-fits-all. Vanessa Lee, RN (and founder of The Things We Do) is back to break down what sets Jeuveau® apart, who it suits, and how it stacks up in recent head-to-head data. (Plus, Sara shares her experience with it so far!) Then, we tackle your Slack Qs: subtle celeb-style tweaks on a budget, microneedling timelines for acne scarring, sun-spot solutions, rosacea care at home, and where high-frequency wands actually fit into your routine.

Vanessa Lee was compensated by Evolus to appear in the first segment of this podcast.

For full Product Information, including Boxed Warning and Medication Guide, visit evolusrx.com. To learn more, visit jeuveau.com. Jeuveau® (prabotulinumtoxinA-xvfs) is an FDA-approved prescription injectable treatment used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in

adults. There are risks with treatment ‒ effects of Jeuveau may spread hours to weeks after injection causing serious symptoms. Alert your doctor right away of difficulty swallowing, speaking, breathing, eye problems or muscle weakness, which can be signs of a life-threatening condition. Other serious risks include allergic reactions, heart or eye problems. The most common side effects are headache, eyelid drooping, upper respiratory infection, and increased white blood cell count. Ask your doctor about Jeuveau and whether it’s right for you.

*About 50% of patients begin showing improvement after two days. Most patients (~69%) achieve complete results by day 30. On average, Jeuveau patients receive three treatments per year.

FTC disclosure: Thank you to Jeuveau for partnering with us on this episode. Intended for US audiences only.

US-JUV-2500517

Watch our episodes!

Shop our episodes

Instagram: @glossangelspod | TikTok: @glossangelespod

Email: glossangelespodcast@gmail.com

Hosted on Acast. See acast.com/privacy for more information.